Future target-based drug discovery for tuberculosis?

@article{Kana2014FutureTD,
  title={Future target-based drug discovery for tuberculosis?},
  author={B. Kana and P. Karakousis and T. Parish and T. Dick},
  journal={Tuberculosis},
  year={2014},
  volume={94 6},
  pages={
          551-6
        }
}
New drugs that retain potency against multidrug/extensively drug-resistant strains of Mycobacterium tuberculosis, with the additional benefit of a shortened treatment duration and ease of administration, are urgently needed by tuberculosis (TB) control programs. Efforts to develop this new generation of treatment interventions have been plagued with numerous problems, the most significant being our insufficient understanding of mycobacterial metabolism during disease. This, combined with… Expand
Mycobacterial drug discovery
TLDR
Traditional and innovative techniques widely used in the quest for new anti-tubercular compounds are discussed, which are now primed to accelerate the discovery of novel hits and leads with known targets and whole cell activity. Expand
Deconvolution of Mycobacterium tuberculosis drug targets using high throughput screening approaches
TLDR
Functional characterisation of a putative enoyl CoA hydratase EchA12, which was targeted by florfenicol, revealed a novel lipid chaperone functionality associated with cell wall lipid biosynthesis, providing further evidence that this enzyme as a viable drug target (Ballell et. al., 2013). Expand
Biosynthesis of Galactan in Mycobacterium tuberculosis as a Viable TB Drug Target?
TLDR
This review summarizes the current knowledge on galactan biosynthesis in Mycobacterium tuberculosis, including landmark findings that led to the discovery and understanding of three key enzymes in this pathway: UDP-galactose mutase, and galactofuranosyl transferases GlfT1 and Glft2, and recapitulate the efforts aimed at their inhibition. Expand
Early Drug Development and Evaluation of Putative Antitubercular Compounds in the -Omics Era
TLDR
How methods of DNA and RNA sequencing, proteomics, and genetic manipulation of organisms increase the authors' understanding of mechanisms of action of antibiotics and allow the evaluation of drugs and how -omic technologies contribute to the emergence of drug resistance is discussed. Expand
Identifying New Probes of Essential Targets in Mycobacterium tuberculosis
TLDR
The field desperately needs compounds with novel mechanisms of action capable of inhibiting multiand extensively-drug resistant Mtb as well as non-replicating Mtb. Expand
Pyridine and quinoline molecules as crucial protagonists in the never-stopping discovery of new agents against tuberculosis.
TLDR
The most significant advances in the design of new compounds able to efficiently kill Mtb via a disruption of new diverse biological targets are reviewed, discussing briefly their physicochemical parameters calculated by available Molinspiration software. Expand
Tuberculosis Drug Discovery: A Decade of Hit Assessment for Defined Targets
TLDR
Scaffolds that have been identified over the last decade from screens of small molecule libraries against Mtb or defined targets where mechanism of action investigation has defined target-hit couples and structure-activity relationship studies have described the pharmacophore are discussed. Expand
Emerging Approaches to Tuberculosis Drug Development: At Home in the Metabolome.
TLDR
The emerging potential of metabolomics; the systems level study of small molecule metabolites, is discussed to help overcome gaps and serve as a unique biochemical bridge between the phenotypic properties of chemical compounds and biological targets. Expand
The Prospect of Repurposing Immunomodulatory Drugs for Adjunctive Chemotherapy against Tuberculosis: A Critical Review
TLDR
This article explores and discusses the molecular entities that have shown promise in being repurposed for use in anti-TB adjunctive therapy and aims to provide the most up-to-date picture of their progress. Expand
Spirocycle MmpL3 Inhibitors with Improved hERG and Cytotoxicity Profiles as Inhibitors of Mycobacterium tuberculosis Growth
TLDR
The novel N-alkylated pyrazole portion offered improved physicochemical properties, and optimization led to identification of a zwitterion series, exemplified by lead 29, with decreased HepG2 cytotoxicity as well as limited hERG ion channel inhibition. Expand
...
1
2
3
4
...

References

SHOWING 1-10 OF 56 REFERENCES
Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis
TLDR
The optimized IPA compound Q203 inhibited the growth of MDR and XDR M. tuberculosis clinical isolates in culture broth medium in the low nanomolar range and was efficacious in a mouse model of tuberculosis at a dose less than 1 mg per kg body weight, which highlights the potency of this compound. Expand
Rational development of adjunct immune-based therapies for drug-resistant tuberculosis: hypotheses and experimental designs.
The poor treatment outcomes for extensively drug-resistant and multidrug-resistant tuberculosis and the slow progress in development and evaluation of new tuberculosis drugs gave rise to developmentExpand
Multitarget Drug Discovery for Tuberculosis and Other Infectious Diseases
TLDR
It is shown that 1 and the new compounds also target enzymes involved in menaquinone biosynthesis and electron transport, inhibiting respiration and ATP biosynthesis, and are uncouplers, collapsing the pH gradient and membrane potential used to power transporters. Expand
TMC207 becomes bedaquiline, a new anti-TB drug.
TLDR
Bedaquiline, formerly TMC207, is a new diarylquinoline antibiotic with specific activity against Mycobacterium tuberculosis and several nontuberculous mycobacteria, which has recently received accelerated approval for the treatment of pulmonary multidrug-resistant TB in adults. Expand
Tuberculosis drug discovery in the post-post-genomic era
TLDR
In the post‐post‐genomics era, more advanced technologies have been implemented and these include high‐content screening, screening for inhibitors of latency, the use of conditional knock‐down mutants for validated targets and siRNA screens, and immunomodulation and pharmacological manipulation of host functions are being explored in an attempt to widen therapeutic options. Expand
Sustainable tuberculosis drug development.
  • R. Wallis
  • Medicine
  • Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2013
TLDR
A novel regimen with the potential for use in both drug-sensitive (DS) and DR tuberculosis based on 2-month sputum culture would shorten time to initial approval by several years and a global outcomes registry would confirm safety and effectiveness in both DS andDR tuberculosis, making possible the second transformation of tuberculosis treatment. Expand
How antibacterials really work: impact on drug discovery.
TLDR
These initial findings suggest that antibacterials have an ‘extended’ mechanism of action beyond the well-known modulation of their primary targets, which could explain why they have failed in the past. Expand
Pathway-selective sensitization of Mycobacterium tuberculosis for target-based whole-cell screening.
TLDR
Stable reporter strains were generated for use in high-throughput screening, and their utility was demonstrated by identifying compounds that display greater potency against a PanC-depleted strain. Expand
PA-824, moxifloxacin and pyrazinamide combination therapy for tuberculosis
TLDR
The rationale for this novel study is reviewed, the development strategy for PA-824 is discussed, the study findings and its implications for future development of this regimen are highlighted and how this study informs the development pathway for future novel TB regimens are highlighted. Expand
Identification of Novel Imidazo[1,2-a]pyridine Inhibitors Targeting M. tuberculosis QcrB
TLDR
Through the use of high throughput whole cell screening of an extensive compound library a number of imidazo[1,2-a]pyridine compounds were obtained as potent lead molecules active against M. tuberculosis and Mycobacterium bovis BCG demonstrating a common target. Expand
...
1
2
3
4
5
...